Certara, Inc. Stock Price, News & Analysis

Certara, Inc. (Nasdaq: CERT) announced the successful closure of its public offering, selling 23,000,000 shares at $31.00 each, generating approximately $139.5 million in gross proceeds. This total includes an additional 3,000,000 shares from underwriters' option. Certara sold 4,500,000 shares while selling stockholders contributed 18,500,000 shares. The proceeds will be utilized for general corporate purposes, including acquisitions. The offering was managed by Jefferies, Morgan Stanley, and BofA Securities, among others.

Certara, Inc. (Nasdaq: CERT) has announced its public offering of 4.5 million shares, priced at $31.00 each, aiming for gross proceeds of approximately $139.5 million. Additionally, existing stockholders are offering 15.5 million shares, with underwriters given a 30-day option for an extra 3 million shares. The net proceeds will support general corporate purposes, including acquisitions. The offering is led by Jefferies, Morgan Stanley, and BofA Securities, with closing expected on or around September 13, 2021.

Certara, Inc. (Nasdaq: CERT) announced a proposed underwritten public offering of 20 million shares of its common stock. Certara aims to offer 4.5 million shares directly, while selling stockholders will offer 15.5 million shares. Additionally, there is a potential for underwriters to purchase up to 3 million additional shares. The net proceeds from the shares offered by Certara will be used for general corporate purposes including acquisitions. The offering is led by Jefferies, Morgan Stanley, and BofA Securities.

Certara, a leader in biosimulation, announced participation in upcoming virtual investor conferences. Key events include the Morgan Stanley Global Healthcare Conference on September 14 at 9:30 a.m. ET, featuring CEO William Feehery and CFO Andrew Schemick; the Baird Global Healthcare Conference on September 15 at 4:55 p.m. ET, with CFO Andrew Schemick; and the Bank of America Securities Drug Discovery Conference on September 20 at 8:00 a.m. ET, with both executives. Live webcasts will be available on Certara’s investor relations website for 90 days.

Certara, Inc. (Nasdaq: CERT) reported Q2 2021 revenue of $70.1 million, a 15% increase year-over-year. Net loss was $2.9 million, contrasting with a net income of $2.8 million in Q2 2020. Adjusted EBITDA rose 1% to $25.5 million. The company announced the acquisition of Pinnacle 21 for $310 million, aimed at enhancing its data standardization capabilities. Full year 2021 guidance was raised to $283-$289 million in revenue, $101-$103 million in Adjusted EBITDA, and $0.21-$0.25 in Adjusted Diluted EPS, excluding Pinnacle 21's impact.

Certara, Inc. (Nasdaq: CERT) has announced a definitive agreement to acquire Pinnacle 21 for $310 million in cash and stock. The acquisition, aimed at enhancing Certara's biosimulation and regulatory software capabilities, is expected to be immediately accretive to revenue and adjusted EBITDA margins. Pinnacle 21's tools ensure compliance with CDISC standards, crucial for FDA and PMDA drug submissions. The deal, which has been unanimously approved, is expected to close by early Q4 2021, subject to regulatory approvals.

Certara (NASDAQ: CERT) has announced a $250 million investment from Mubadala Investment Company, with shares priced at $26 each. The transaction includes the purchase of 9,615,384 shares from existing shareholders, expected to close on August 2, 2021. CEO William F. Feehery expressed enthusiasm for Mubadala's support, highlighting Certara's leadership in biosimulation. Mubadala's investment aims to enhance innovation in clinical needs and improve drug development processes. With over 1,650 clients globally, Certara continues to advance biopharma research and development.

Certara has confirmed through the Pitch study at Oxford University that its Vaccine Simulator predicted an optimal eight-week interval between COVID-19 vaccine doses. This finding challenges the existing dosing schedules of Pfizer-BioNTech and Moderna, which recommend three and four weeks, respectively. Certara's biosimulation technology integrates various data to optimize dosing strategies, aiding in global health efforts amidst the pandemic. The company aims to enhance vaccine efficacy and safety, including future booster recommendations and mixing vaccines.

Certara has appointed Nancy Killefer and Cynthia Collins to its board of directors, effective August 1, 2021, increasing the board to eleven members. Killefer brings over 30 years of executive experience in pharmaceuticals and healthcare, previously serving as a director at McKinsey & Company. Collins, with over 40 years in biotechnology, was CEO at Editas Medicine, where she led significant advancements in gene editing. Both directors aim to leverage their expertise to enhance Certara's drug discovery and development processes.